1. Pivotal Data Highlights on Myeloproliferative Neoplasms Myelofibrosis

2. Activity Goals

3. Prognosis: CALR MF is a Distinct Entity

4. Clinical Effect of Founding Driver Mutations in MF

5. Phase 1b: Panobinostat and Ruxolitinib in MF

6. Novel Combination: PRM-151 + RUX

13. ET: Molecular Markers

14. ET: Impact of Treatment on Molecular Markers

15. Prognosis and Risk Stratification

16. Splanchnic Vein Thrombosis

17. Pivotal Data Highlights on Acute Myeloid Leukemia FLT3 Inhibition

18. Phase 2: Efficacy of Quizartinib in Relapsed/ Refractory AML

19. Quizartinib as a Bridge to HCT in FLT3-ITD(+) AML

20. Pivotal Data Highlights on Acute Myeloid Leukemia New Agents for Older Patients

21. Phase I/2 Study of Volasertib

22. Phase 2:Efficacy and Safety of SGI-110

23. Abbreviations

24. Abbreviations (cont)

25. Abbreviations (cont)

26. References

27. References (cont)

28. References (cont)

29. References (cont)

30. References (cont)

31. References (cont)

32. References (cont)

33. References (cont)

34. References (cont)

35. References (cont)